Stocktoria
Immunovant, Inc. IMVT
Immunovant, Inc. (IMVT) earns a Piotroski F-score of 2/9 (weak financial health). It does not currently pay a dividend.
Quality score trend · recomputed for each fiscal year
Each year's score is computed from that year's filing — a rising Piotroski F or Altman Z″ means improving financial health, a fall is worth a look.
Analyst price target
Recent analyst actions
| Date | Firm | Rating |
|---|---|---|
| 2026-06-30 | Citigroup | Buy (main) |
| 2026-05-26 | Guggenheim | Buy (main) |
| 2026-05-22 | Truist Securities | Hold (main) |
| 2026-05-21 | B of A Securities | Buy (main) |
| 2026-05-21 | HC Wainwright & Co. | Buy (main) |
| 2026-04-15 | Goldman Sachs | Neutral (main) |
Wall Street analyst consensus — a sentiment gauge, not our scoring.
How it ranks in Manufacturing · percentile among 1957 companies
Percentile vs other Manufacturing companies we cover — e.g. “stronger than 90%” means only 10% score higher on that measure.
Piotroski F breakdown · 2/9 tests passed
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Sector peers · similar-size Manufacturing companies compare side by side →
| Ticker | Company | Piotroski F | Altman Z″ | P / E | Revenue growth |
|---|---|---|---|---|---|
| IMVT | Immunovant, Inc. | 2/9 | — | — | — |
| AMGN | AMGEN INC | 6/9 | 0.14 | 25.1 | +10% |
| GILD | GILEAD SCIENCES, INC. | 7/9 | 3.28 | 18.7 | +2.4% |
| BIIB | BIOGEN INC. | 4/9 | — | 24.7 | +2.2% |
| NBIX | NEUROCRINE BIOSCIENCES INC | 5/9 | 6.21 | 35.4 | +21.4% |
| EXEL | EXELIXIS, INC. | 6/9 | 7.69 | 17.6 | +7% |
| QGEN | QIAGEN N.V. | 7/9 | 5.06 | 19.1 | +5.7% |
About Immunovant, Inc.
Immunovant, Inc., a clinical-stage immunology company, develops targeted therapies to meet the needs of people with autoimmune diseases. It develops IMVT-1402, a human monoclonal antibody that inhibits neonatal fragment crystallizable receptor for graves' disease, rheumatoid arthritis, sjögren's disease, cutaneous lupus erythematosus disease, myasthenia gravis, and chronic inflammatory demyelinating polyneuropathy. The company was founded in 2018 and is based in Durham, North Carolina. Immunovant, Inc. operates as a subsidiary of Roivant Sciences Ltd.
FAQ
Is IMVT financially healthy?
Immunovant, Inc.'s Piotroski F-score is 2/9 (8–9 is excellent, 0–3 weak).
Does IMVT pay a dividend?
No, Immunovant, Inc. does not currently pay a dividend.
How profitable is IMVT?
In FY2026, Immunovant, Inc. had a return on equity of -59.3%.
What is the analyst price target for IMVT?
The average Wall-Street price target for Immunovant, Inc. is $46.00, about 8.0% above the recent price, from 17 analysts (consensus: buy).
Is IMVT a good stock to buy?
Stocktoria doesn't give buy or sell advice, but here is the data on Immunovant, Inc.: a Piotroski F-score of 2/9. Weigh these quality and valuation signals against your own goals.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.